Gland Pharma is currently trading at RS. 1994.30, up by 29.85 points or 1.52% from its previous closing of RS. 1964.45 on the BSE.

The stock opened at RS. 2029.60 and touched an intraday high of RS. 2090.20 and a low of RS. 1980.00. So far, 23,625 shares have been traded on the counter.

This BSE group 'A' stock, with a face value of RS. 1, reached a 52-week high of RS. 2220.95 on August 6, 2024, and a 52-week low of RS. 1200.00 on April 7, 2025. Over the past week, the stock has fluctuated between a high of RS. 2099.00 and a low of RS. 1933.85. The current market capitalization of the company stands at RS. 32,952.11 crore.

In terms of shareholding, promoters hold 51.83% of the company, while institutions hold 40.25% and non-institutions hold 7.93%.

Financially, Gland Pharma has posted a 20.79% year-on-year increase in standalone net profit to RS. 269.26 crore for the quarter ended June 30, 2025, as compared to RS. 222.92 crore in the same period last year. The total income rose by 3.12% to RS. 1093.58 crore in Q1FY26, up from RS. 1060.51 crore in the corresponding quarter of the previous year.

On a consolidated basis, the company reported a sharp 49.89% jump in net profit at RS. 215.48 crore for Q1FY26, compared to RS. 143.76 crore in Q1FY25. Total consolidated income increased by 7.57% to RS. 1563.15 crore, from RS. 1453.14 crore in the same period last year.